Who we are

Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of a COVID-19 drug FYB207

About Biosimilars:
Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of approximately USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Global sales of biosimilars are estimated to exceed $15 billion by 2020. By 2030, analysts estimate that this figure could rise to over $60 billion.

Contact:
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg
Germany
phone +49 (0) 89 - 86 46 67 100 
fax + 49 (0) 89 - 86 46 67 110
info@formycon.com

Biotechnology

Formycon AG

Stefan Glombitza

Sven Brenner

Mauro Sergi

Veronika U.

Andreas Seidl

Enno Spillner

Marta Blamowska

Sigrid Balser

The Scientific R&D Team at Formycon AG is responsible for the research and development of high-quality biosimilars and innovative biopharmaceutical medicines. This team performs critical tasks such as mass spectrometry analysis, stability coordination, physicochemical characterization, quality control, and drug product process development. They work collaboratively to advance biopharmaceutical projects from the early stages of technical development through to clinical trials and regulatory submissions, ensuring the creation of vital and affordable treatments for chronic diseases.

Scientific R&D Team

Preclinical and Process Sciences

Clinical Development and Operations

Scientific R&D Team

About

Team members

Other teams at Formycon AG

Preclinical and Process Sciences

Clinical Development and Operations